Conquer Cancer Fdn Of The American Society Of Clinical Oncology
- Assets
- $98.1m
- Revenue
- $33.1m
- Investments
- $0.0
- Employees
- 0
- Location
- Alexandria, VA
- Founding
- 10/1999
- Data as of
- 12/2022
- EIN
- 31-1667995
Organization Overview
Conquer Cancer Fdn Of The American Society Of Clinical Oncology, operating under the name Conquer Cancer & Conquer Cancer Fdtn, is located in Alexandria, VA. The organization was established in 1999. According to its NTEE Classification (H11) the organization is classified as: Single Organization Support, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Conquer Cancer & Conquer Cancer Fdtn is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Conquer Cancer & Conquer Cancer Fdtn generated $33.1m in total revenue. This represents relatively stable growth, over the past 8 years the organization has increased revenue by an average of 1.0% each year. All expenses for the organization totaled $32.9m during the year ending 12/2022. While expenses have increased by 1.1% per year over the past 8 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Conquer Cancer & Conquer Cancer Fdtn has awarded 313 individual grants totaling $109,785,245. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
TO ACCELERATE BREAKTHROUGHS IN LIFESAVING RESEARCH AND EMPOWER PEOPLE EVERYWHERE TO CONQUER CANCER.
Describe the Organization's Program Activity:
Part 3 - Line 4a
SEE SCHEDULE O:RESEARCH: RESEARCH IS HOW WE CONQUER CANCER. IT MEANS EVERYTHING, FROM UNDERSTANDING HOW CANCER IMPACTS CERTAIN PEOPLE TO FINDING GROUNDBREAKING NEW WAYS TO TREAT CANCER. THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $158 MILLION IN CANCER RESEARCH GRANTS TO OVER 2,600 RECIPIENTS IN 80 COUNTRIES. HIGHLIGHTS OF 2022 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE:RESEARCH PROFESSORSHIP (RP): $500,000 PROVIDED ONE (1) FIVE-YEAR AWARD TO AN OUTSTANDING RESEARCHER WHO HAS MADE, AND IS CONTINUING TO MAKE, SIGNIFICANT CONTRIBUTIONS IN BREAST CANCER RESEARCH AND WILL DEDICATE THEIR TIME IN TRAINING FUTURE BREAST CANCER RESEARCHERS. THIS PROFESSORSHIP IS DESIGNED WITH THE PRIMARY GOAL OF INCREASING DIVERSITY IN THE LEADERSHIP OF THE ONCOLOGY WORKFORCE AND CANCER RESEARCH. *ADVANCED CLINICAL RESEARCH AWARD (ACRA): $900,000 PROVIDED TWO (2) THREE-YEAR AWARDS TO SUPPORT PHYSICIAN-SCIENTISTS COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH WITH A PATIENT-ORIENTED FOCUS. BOTH AWARDS SUPPORTED DIVERSITY/INCLUSION, FOCUSING ON BREAST CANCER. *CAREER DEVELOPMENT AWARD (CDA): $4,400,000 PROVIDED TWENTY-TWO (22) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH TO CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. *YOUNG INVESTIGATOR AWARD (YIA): $4,820,000 PROVIDED NINETY-SIX (96) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. *GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD: $291,500 PROVIDED SIX (6) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS.THIS IS A MENTORED AWARD AND THE RESEARCH PROJECT IS CONDUCTED UNDER THE GUIDANCE OF A SCIENTIFIC MENTOR. *INTERNATIONAL INNOVATION GRANT: $94,838 PROVIDED FIVE (5) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO POTENTIALLY DISCOVERING INTERVENTIONS TRANSFERABLE TO CLINICAL CARE IN OTHER LOW OR MIDDLE RESOURCE COUNTRY SETTINGS.THROUGH ITS EVERYGRANT PROGRAM, CONQUER CANCER UTILIZES ITS EXPERTISE IN GRANTS ADMINISTRATION AND PROGRAM MANAGEMENT TO COLLABORATE WITH OTHER ORGANIZATIONS TO DEVELOP AND DELIVER PROGRAMS THAT MAKE A DIFFERENCE TO CANCER CARE TEAMS AND PATIENTS EVERYWHERE.
SEE SCHEDULE O:PROFESSIONAL EDUCATION: CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS AND LATEST DEVELOPMENTS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH MEETINGS AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2022 INCLUDE THE FOLLOWING: * ASCO ANNUAL MEETING: THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY WITH MORE THAN 42,000 PARTICIPANTS WORLDWIDE IN 2022. THE ANNUAL MEETING PROVIDES A FORUM TO JOIN GLOBAL CANCER EXPERTS AND DISCOVER THE LATEST INNOVATIONS IN CANCER RESEARCH AND EDUCATION WHILE ADDRESSING THE NEED FOR EVERY PATIENT TO RECEIVE THE HIGHEST QUALITY CANCER CARE AVAILABLE. *GASTROINTESTINAL CANCERS (GI) SYMPOSIUM: THIS IS THE PREMIER MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING. THE GI SYMPOSIUM GIVES HEALTHCARE PROVIDERS ACROSS MULTIPLE DISCIPLINES AND PROFESSIONS THE OPPORTUNITY TO RECEIVE CRITICAL UPDATES AND RECOMMENDATIONS TO IMPROVE THE CARE OF PATIENTS WITH GI CANCERS. *GENITOURINARY CANCERS (GU) SYMPOSIUM: THIS IS THE PREEMINENT GENITOURINARY ONCOLOGY EVENT, ADDRESSING THE MULTIDISCIPLINARY NEEDS OF PHYSICIANS AND OTHER MEMBERS OF THE CANCER CARE AND RESEARCH COMMUNITY WHO DIAGNOSE, TREAT, AND STUDY GENITOURINARY MALIGNANCIES. THE GU SYMPOSIUM PROVIDES THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS. *QUALITY CARE SYMPOSIUM: THIS IS AN UNPARALLELED OPPORTUNITY TO LEVERAGE THE MOST UP-TO-DATE SCIENCE AND DISCOVER PROVEN STRATEGIES AND TOOLS CRITICAL TO MAKING KEY DECISIONS THAT CAN REDUCE DISPARITIES IN CARE FOR EVERY PATIENT, EVERY DAY, EVERYWHERE. *MERIT AWARDS: 240,000 PROVIDED TWO HUNDRED THIRTY-SIX (236) MERIT AWARDS PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA. *MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR): $238,000 PROVIDED TWENTY-EIGHT (28) MEDICAL STUDENT ROTATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER.
SEE SCHEDULE O:QUALITY & ACCESS TO CARE: REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE THAT ARE UNDERSERVED.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Clifford A Hudis MD Executive Vice Chair | OfficerTrustee | 6.5 | $0 |
Amy C Peterson MD Secretary | OfficerTrustee | 1 | $0 |
Alexander W Casdin Treasurer | OfficerTrustee | 1 | $0 |
Kathryn Beal Board Member | Trustee | 1 | $0 |
Richard J Boxer MD Board Member | Trustee | 1 | $0 |
Riccardo Braglia Board Member | Trustee | 1 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
True North Inc Media Buy Solicitations | 12/30/22 | $1,515,499 |
Faircom Ny Direct Mail Solicitations | 12/30/22 | $945,473 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $3,954 |
| Membership dues | $1,269,000 |
| Fundraising events | $1,676,299 |
| Related organizations | $3,514,500 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $24,661,435 |
| Noncash contributions included in lines 1a–1f | $37,345 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $31,125,188 |
| Total Program Service Revenue | $363,476 |
| Investment income | $1,978,770 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | -$141,082 |
| Net Income from Fundraising Events | -$192,660 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $33,133,692 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $18,880,794 |
| Grants and other assistance to domestic individuals. | $413,000 |
| Grants and other assistance to Foreign Orgs/Individuals | $1,354,838 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $7,148,827 |
| Fees for services: Legal | $3,000 |
| Fees for services: Accounting | $68,500 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $257,693 |
| Fees for services: Investment Management | $40,300 |
| Fees for services: Other | $1,932,897 |
| Advertising and promotion | $17,235 |
| Office expenses | $1,296,393 |
| Information technology | $632,003 |
| Royalties | $0 |
| Occupancy | $490,964 |
| Travel | $296,735 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $54,949 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $0 |
| All other expenses | $800 |
| Total functional expenses | $32,888,928 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $9,023,972 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $5,402,813 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $130,103 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $83,560,282 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $98,117,170 |
| Accounts payable and accrued expenses | $160,281 |
| Grants payable | $3,179,628 |
| Deferred revenue | $8,376,287 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $2,715,846 |
| Total liabilities | $14,432,042 |
| Net assets without donor restrictions | $34,722,323 |
| Net assets with donor restrictions | $48,962,805 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $98,117,170 |
Grants Awarded
Over the last fiscal year, Conquer Cancer Fdn Of The American Society Of Clinical Oncology has awarded $19,072,574 in support to 44 organizations.
| Grant Recipient | Amount |
|---|---|
BAYLOR COLLEGE OF MEDICINE PURPOSE: YIA | $48,369 |
BRIGHAM AND WOMEN'S HOSPITAL INC PURPOSE: YIA | $100,000 |
CEDARS-SINAI MEDICAL CENTER PURPOSE: CDA | $200,000 |
THE CHILDREN'S HOSPITAL OF PHILADELPHIA PURPOSE: YIA | $50,000 |
COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK PURPOSE: ASCO REGISTRY RESEARCH GRANT, CDA, YIA | $250,000 |
DUKE UNIVERSITY PURPOSE: MSR, ACRA | $50,000 |